Fig. 3

Differences in the levels of specific CSF metabolites. Differences in the levels of succinate, malic acid, alanine and lactic acid between 40 CSF samples from patients with no history of cancer (controls) or patients with gliomas IDH-WT, gliomas IDH-mutant, or metastatic lung or breast cancer to the CNS. Succinate and malic acid are elevated in all but one of the samples from patients with IDH-mutant glioma, in comparison to patients with IDH-WT gliomas, or controls. In contrast, alanine levels are reduced in CSF samples from patients with IDH-mutant gliomas or metastatic lung or breast carcinomas, in comparison to control CSF samples. Lactic acid levels were elevated in a subset of CSF samples from patients with IDH-mutant gliomas, in comparison to controls or patients with other cancer types. The Y-axis represents normalized log2 transformed values